Showing 3611-3620 of 5621 results for "".
- Karen Petrou Appointed Board Chair of the Foundation Fighting Blindnesshttps://modernod.com/news/karen-petrou-appointed-board-chair-of-the-foundation-fighting-blindness/2482334/The Foundation Fighting Blindness announced the appointment of Karen Petrou as Board Chair, effective July 1, 2024. Petrou succeeds David Brint, who is retiring after 8 years of service. Ms. Petrou’s becomes the third person to hold the position in the Foundation&rs
- Rayner Closes Recruitment for IDE for RayOne EMV Toric IOLshttps://modernod.com/news/rayner-closes-recruitment-for-ide-for-rayone-emv-toric-iols/2482332/Rayner announced that it has closed recruitment in the investigational device exemption (IDE) study for its EMV Toric IOL in the US. The study will ultimately enable the introduction of the RayOne EMV Toric lens for use in the US. Developed in collaboration with Professor
- Notal Vision Announces Results From Prospective Trial Using Home-Based OCThttps://modernod.com/news/notal-vision-announces-results-from-prospective-trial-using-home-based-oct/2482331/Notal Vision announced the results from the first prospective clinical trial using home-based optical coherence tomography (OCT) to manage wet age-related macular degeneration (AMD) patients in an investigational setting. The results, which were published in Retina, demonstrated a
- FDA Clears Alcon's Unity Vitreoretinal-Cataract System and Standalone Cataract Systemhttps://modernod.com/news/fda-clears-alcons-unity-vitreoretinal-cataract-system-and-unity-standalone-cataract-system/2482329/Alcon announced that its Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) have received FDA 510(k) clearance. The new devices are the first to be introduced from Alcon’s Unity portfolio and represent Alcon's next generation of e
- Ocugen Doses First Patient in Phase 3 Clinical Trial for OCU400 Gene Therapy for RPhttps://modernod.com/news/ocugen-doses-first-patient-in-phase-3-clinical-trial-for-ocu400-gene-therapy-for-retinitis-pigmentosa/2482326/Ocugen announced that the first patient has been dosed in its phase 3 liMeliGhT clinical trial for OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “Each clinical milestone achieved by OCU400 brings us closer to providing a one-
- Neurotech Receives Priority Review of BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)https://modernod.com/news/neurotech-receives-priority-review-of-biologics-license-application-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2-mactel/2482324/The FDA has granted priority review of Neurotech Pharmaceuticals's biologic license application (BLA) for NT-501 (revakinagene taroretcel), an investigational encapsulated cell therapy for the treatment of Macular Telangiectasia Type 2 (MacTel). The designation m
- J&J's Nipocalimab Significantly Improves Sjögren’s Disease Activity in a Phase 2 Studyhttps://modernod.com/news/jjs-nipocalimab-significantly-improves-sjogrens-disease-activity-in-a-phase-2-study/2482323/Johnson & Johnson announced that patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the phase 2 DAHLIAS dose-rang
- 2024 Kavli Prize in Neuroscience Awarded for the Discovery of 'Face Areas' in the Brainhttps://modernod.com/news/2024-kavli-prize-in-neuroscience-awarded-for-the-discovery-of-face-areas-in-the-brain/2482322/The 2024 Kavli Prize in Neuroscience honors Nancy Kanwisher, PhD, (Massachusetts Institute of Technology); Doris Ying Tsao, PhD (University of California, Berkeley); and Winrich Freiwald, Ph.D. (Rockefeller University) for the discovery of a specialized system within the brain to r
- Skye Fails Phase 2 Glaucoma Trial; Shifts Focus to Obesityhttps://modernod.com/news/skye-fails-phase-2-glaucoma-trial-shifts-focus-to-obesity/2482317/Skye Bioscience announced that its phase 2a clinical trial of SBI-100 ophthalmic emulsion in patients with primary open-angle glaucoma or ocular hypertension did not meet its primary endpoint for lowering IOP. As a result, Skye intends to discontinue clinical development and spendi
- B+L Introduces INFUSE for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-introduces-infuse-for-astigmatism-silicone-hydrogel-daily-disposable-contact-lenses/2482316/Bausch + Lomb has introduced 'INFUSE for Astigmatism' daily disposable contact lenses in the US. Engineered with a next-generation lens material infused with ProBalance Technology and the company’s proprietary OpticAlign design, Bausch + Lomb says INFUSE for